Zhu ZhiYun – General Manager, Zambon China
Zhu ZhiYun, general manager of Zambon China, shares the growth of Zambon China from a manufacturing facility – when he joined in 2005 – to the fully-fledged commercial affiliate it…
Address: No.97,Lane 1518,Guangfulin Road,Songjiang District,Shanghai,201620,P.R.China
Tel: 86 2161 026 752
Web: http://www.hoborchem.com/
Shanghai Hobor Chemical Co., Ltd is a production-oriented enterprise dedicated to pharmaceutical intermediates and active pharmaceutical ingredients synthesis and process development,Hobor Chemical has been committed to expedite our customer’s R&D and manufacturing in a time and cost effective manner since 2010 the company started.We focuses on developing efficient process technology for intermediates,active ingredients.
Our R&D lab located in Hi-Tech Park of Shanghai,China,the facility located in Fengxin industrial area,Jiangxi Province,employees experienced chemistry and medicine R&D team and equipped with the state of the art instruments.to be able to complete the low temperature of -80 to 300 high temperature a variety of reactions.Our products are strictly controlled by the LC, NMR,MS ensure customer satisfaction with every batch of products. We have established very good relationship with many global customers since company started.
Custom Synthesis As a innovative research company and active high-tech building block supplier, we are eager to become your professional partner in the following fields:
1. Heterocyclic chemistry and it’s synthetic technology
2. APi’s structure and it’s process research3. Cost effective process for pharma intermediates4. Chiral chemicals realted to above region
We provide Explore new synthetic chemistry Synthesis of novel and/or know compounds Substantial experience in process development, scale up and commercialization Able to follow an entire project, from laboratory to pilot production
QA manager is always involved in working together with our marketing colleage to identify suitable supplier, ensure the quality of products, and control the risks in supply chain.
Zhu ZhiYun, general manager of Zambon China, shares the growth of Zambon China from a manufacturing facility – when he joined in 2005 – to the fully-fledged commercial affiliate it…
Dr Tianyi (Tee) Zhang, GM of Frontage China and SVP of Frontage Holdings, shares the significant growth of the China affiliate over the past four years; their competitive advantages in…
Dr Jiang Lei and Dr Shou Jianyong, EnnovaBio’s co-founders, introduce their strategy and outline the progress being made in the Chinese biopharma industry at large. We are a Chinese…
Dr Shun Luo, chairman, founder and CEO of Thousand Oaks Biopharmaceuticals, shares the company’s vision to deliver more accessible and affordable biologics to patients globally by lowering the cost of…
Catherine Lee, general manager and managing director of West Pharmaceutical Services China, shares the highlights of her 2.5 years heading West’s China affiliate; West’s commitment to delivering their global scientific…
Following Hansoh’s recent IPO in Hong Kong, CEO Zhong Huijuan and husband Sun Piaoyang, CEO of Jiangsu Hengrui, are now officially the wealthiest couple in China. Sun, a former high…
Dr Jinzi Jason Wu of Ascletis – a Chinese biotech success story that has developed rapidly in recent years – outlines the company’s journey from its founding in 2013 to…
PD-1 inhibitors have boosted survival rates for many cancer patients since their introduction in the US five years ago. Last year, MSD and BMS began selling these expensive therapies in…
More accessible and affordable healthcare for all: China’s government has outlined several proposals to expand healthcare reform in a report released 4th June by the General Office of the State…
The pharmaceutical industries of China and India, historically focused on their large domestic markets and exports to developed nations, are increasingly forging closer links. With US trade tariffs affecting both…
The company sold 551 million shares in the latest IPO on the Hong Kong Exchange and plans to invest half of its earnings in R&D. Hong Kong is now the…
With Hong Kong now established as the world’s second largest funding hub for biotech, at this week’s BIO 2019 conference in Philadelphia, the HKEX’s Michael Chan outlined some of the…
See our Cookie Privacy Policy Here
